Loading
Cannara Biotech Inc. Stock: price and insider trades · Canada
CA·Mcap CA$205.5M
Cannara Biotech Inc.: what insiders have been doing
This page follows insider dealings at Cannara Biotech Inc. as filed with SEDI. Over the twelve months to 18 October 2026, 5 filings were filed, from 3 insiders.
The flow runs one way only: 2 insiders bought (2 purchases totalling €78k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €60k, the purchase published on 31 July 2026 by Olymbec Investments Inc. is the largest of the period (0.044% of market cap). Those buying include 1 major shareholder and 1 senior executive.
The last purchase on record was published on 31 July 2026, which is 78 days ago. Filings reach the SEDI feed a median of 6 days after the trade. Until a filing is published, the market cannot know about the trade.
Across the 2,120 companies tracked on its exchange, the median is 12 filings; at 5 filings, this issuer sits below that mark. The full history, which starts in 2026, counts 2 purchases against no sales.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
5
Thresholds
n/a
Buy Volume
€77,640
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleNicholas Sosiak1 buy
Olymbec Investments Inc.1 buy
Analyst consensus: bullish or bearish?
Analysts rate Cannara Biotech Inc. Strong Buy (bullish), based on 4 analysts. Average price target: CA$3.38.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,379 of 24,158 companies
67.9
score / 100
Value71
Quality65
FCF yld6.8%
Earn yld6.5%
EV/EBITDA8.5x
ROE9.7%
Gross mgn44%
Net mgn12%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended August 2025 · cache
CA$2.08
Analyst consensus
4 analystsStrong buy
CA$3.00Target CA$3.38(+62%)CA$4.00
Income statement
RevenueCA$107.2M
Gross profitCA$47.1M44% margin
EBITDACA$28.5M27% margin
Net incomeCA$13.1M9.3% margin
Valuation
PER (trailing)18.9x
PER (forward)10.2x
P/Book1.6x
Beta0.27
Balance sheet & cash
Market capCA$205.5M
Total debtCA$41.6M
Free Cash FlowCA$13.7M
Debt / Equity29%
Profitability & ownership
ROE9.7%
ROA6.3%
% insiders50.1%
% institutions0.3%
Last declaration on 31 July 2026
Declarations5 total
50,000 shares@ CA$1.930.044% mcap100.0% of flowCommon SharesTSXSEDI:4757370
Canonical exit: 27 Oct 2026 (T+90)
84,600 sharesOptionsTSXSEDI:4751129
500,000 sharesOptionsTSXSEDI:4751127
50,000 shares@ CA$1.800.051% mcap76.1% of flowCommon SharesTSXSEDI:4746039
16,800 shares@ CA$1.7023.9% of flowCommon SharesTSXSEDI:4731488
Canonical exit: 31 Aug 2026 (T+90)
5 of 5 declarations
About Cannara Biotech Inc.
Cannara Biotech Inc. is a Canadian company focused on the production of cannabis-based products. It is listed on the Toronto Stock Exchange under the symbol XTSE.
